Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that intensive immunosuppression in multiple sclerosis patients significantly reduced relapse rates versus pre-treatment expectations, though some required ongoing treatment after tapering.

Treatment with methotrexate and prednisolone led to complete hair regrowth and no relapse for 2 years.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This case report links sorafenib treatment in a 22-year-old man with relapsed acute myeloid leukemia to a rare instance of drug-induced pityriasis rubra pilaris-like eruption.

This research reports that arsenic trioxide achieved a complete remission rate of 87% in patients with relapsed acute promyelocytic leukemia, though its use involves manageable toxicities.

Follicular unit extraction successfully restored hair growth in a leprosy patient without disease relapse.

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

This review discusses the complex etiology and pathogenesis of vitiligo, noting challenges in treatment effectiveness and relapse, and reports no new clinical results.

Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.

Alopecia areata's causes are unclear, treatments exist but relapses are common.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This study reported two cases of alopecia areata where hair regrowth was achieved with zinc gluconate and sulfur amino acids after relapse post-PUVA cessation, suggesting potential zinc responsiveness in some patients.

This report describes onset, regrowth, and relapse patterns in alopecia areata and proposes mechanisms to integrate into current theories, with no new clinical results.

Intradermal PRP significantly improved melasma in dark skin, with lasting results and no relapse after 3 months.

This case report describes a 40-year-old man whose vitiligo and psoriasis responded favorably to ixekizumab after experiencing vitiligo onset and psoriasis relapse during adalimumab treatment.

In this study, a group taking compound ginseng cicada decoction showed significantly lower relapse rates, severity, and itching related to atopic dermatitis over 3 months compared to a control group, and reported improved quality of life with no significant adverse events.

The researchers reported that treating Alopecia Areata patients with the homeopathic remedy Fluoric Acid resulted in substantial hair regrowth and reduced relapse rates over a 6-year period, suggesting it may be an effective alternative to conventional treatments.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

In this study, increased treatment duration with vismodegib was associated with a decreased risk of relapse in patients with advanced or multiple basal cell carcinoma.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study found that most patients with folliculitis decalvans showed improvement and remission with oral antibiotics, although some experienced relapses and required prolonged treatment.

This report examines efforts to enhance the efficacy of topical steroids for alopecia areata using penetration-enhancing vehicles and exceptionally high concentrations, noting systemic steroids often lead to relapses and toxicity.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.

In this retrospective study, oral isotretinoin monotherapy effectively achieved remission in 82% of patients with folliculitis decalvans, with those receiving ≥0.4 mg/kg/day for ≥3 months experiencing better outcomes and less frequent relapse.

This study reports that generalized discoid lupus erythematosus is a recognized canine variant of cutaneous lupus erythematosus, resembling its human counterpart, with varied treatment responses and common relapses.

In this study, both platelet-rich plasma and intralesional corticosteroids improved hair re-growth in alopecia areata patients, but the difference between treatments was not significant, with fewer relapses observed in the platelet-rich plasma group.